Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269438 · ClinicalTrials.gov registry record · Phase 3
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT00269438 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 225 participants.
The verdict
NCT00269438, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 8 weeks of therapy.
Interventions
- DRUG 5 ASA, enemas, suppositories, corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00269438
The ClinicalTrials.gov registry entry for NCT00269438 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5 ASA, enemas, suppositories, corticosteroids is the first listed.
NCT00269438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00269438 about?
NCT00269438 is a clinical study titled "New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis". The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 8 weeks of therapy.
What is the current status of trial NCT00269438?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2005-12. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00269438?
The interventions under investigation include: 5 ASA, enemas, suppositories, corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00269438?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.